



FOR IMMEDIATE RELEASE

T2 Biosystems Announces the Presentation of Data on Direct Detection with T2Candida

—Data Presented at Infectious Disease Society of America—

Lexington, MA, October 21, 2011 – T2 Biosystems, a company developing direct detection products for superior diagnostics, today announced the presentation of data on its T2MR platform for detection of infectious diseases at the 49th Annual Meeting of the Infectious Disease Society of America (IDSA) in Boston, MA, October 20-23, 2011. Two independent research groups from Massachusetts General Hospital and University of Houston College of Pharmacy used the T2MR platform to analyze whole blood specimens from patients with 5 different types of *Candida* spp. infections. The T2MR platform provided rapid, sensitive, and specific *Candida* species detection results from whole blood samples compared with current detection methods.

The presentations at IDSA analyzed infected patient samples using the T2Candida assay on the T2MR platform. The results from Massachusetts General Hospital and University of Houston College of Pharmacy were both in concordance with blood culture, providing species-specific results in roughly two hours. “These results demonstrate the high specificity and sensitivity of T2 Bio’s diagnostic technology, which may be applied to any immunoassay or molecular target,” said Kevin Garey, Chair, Department of Clinical Sciences and Administration at the University Of Houston College Of Pharmacy. “These data also highlight the potential of the T2Candida assay to dramatically reduce morbidity and mortality associated with candidemia by enabling physicians to rapidly deliver appropriately targeted therapy.”

“These new data further demonstrate that the T2MR platform can dramatically speed up identification of candidemia in patients with *Candida* infections, which we believe will result in truly meaningful clinical benefits,” said John McDonough, CEO of T2 Biosystems. “These results also highlight the tremendous potential for automated detection of targets on the T2MR platform, enabling a wide range of accurate and efficient disease detection for improved response time and treatments. We expect to initiate a large-scale clinical trial of the T2Candida assay and the T2Dx instrument in 2012, and we are actively expanding our T2 molecular and immunoassay pipelines while pursuing optimal partnerships to apply our technology to additional areas of medical need.”

Candida is a blood-borne pathogen associated with approximately 90,000 cases of candidemia in the US annually. Currently, candidemia has an approximate 40% mortality rate, largely due to the elapsed time from *Candida* infection to positive diagnosis and treatment. Current detection methods rely on blood culture, a process



that can take two to five days before identifying a *Candida* infection. The T2MR platform is able to detect *Candida* directly from whole blood without the limits experienced with optical detection technology, even at low copy numbers, and provide results within two hours.

Presentations at IDSA

Saturday, October 22, 2011, 11:45 AM – 1:45 PM ET, Poster Hall B1, #1024: *Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients* by Kevin W. Garey, PharmD, MS, University of Houston College of Pharmacy

Saturday, October 22, 2011, 11:45 AM – 1:45 PM ET, Poster Hall B1, #1026: *Diagnosis of sequential candidemia with the use of NMR biosensor* by Eleftherios Mylonakis, MD, PhD, Massachusetts General Hospital

About T2 Biosystems

T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR, the Company's proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate, and rapid assay results. The Company's products detect molecular or immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians' offices. For more information, please visit www.t2biosystems.com.

Media Contact:

Chris Erdman
MacDougall Biomedical Communications
781-235-3060
cerdman@macbiocom.com

###